Patrick Aloy, ICREA researcher at IRB Barcelona, has told the programme 'L'Entrevista', broadcasted by “La Xarxa Televisió”, that research into Alzheimer’s disease is still unravelling the disease, how it starts and what would be a suitable approach to tackle it."
Because of the complexity of this condition, Aloy says, "we will not cure Alzheimer’s disease. We have to focus on halting its progression. The earlier we stop the development of this condition, the greater the improvement in the health of those who suffer from it."
"To halt its progression, we will be able to administer drugs when symptoms of the disease are detected, thereby preventing its further development. If we had markers to detect the disease 15 years before its onset, we would be able to stop its progression. We wouldn’t be curing the disease but we would be halting its progression before symptoms appear."
See the interview:
La Xarxa (in Catalan)
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).